20:10 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest inhibiting MAPK could help treat autism. In a mouse model of autism, subcutaneous injection with a tool compound MAPK inhibitor decreased numbers of cortical progenitor cells and behavioral deficits and...
17:13 , Jul 20, 2018 |  BC Week In Review  |  Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an upfront...
10:02 , Jul 18, 2018 |  BC Extra  |  Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an upfront...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; melanoma Mouse studies suggest combining Mekinist trametinib with MAPK and CRAF inhibitors could help treat BRAF-dependent lung cancer and melanoma. In six PDX mouse models of BRAF-dependent lung cancer and five of BRAF-dependent...
21:51 , Feb 10, 2017 |  BC Week In Review  |  Company News

Q BioMed, Oklahoma Medical Research Foundation, RGCB deal

Q BioMed partnered with the non-profit Oklahoma Medical Research Foundation and the Indian government-owned RGCB to develop uttroside B, a preclinical chemotherapeutic, and its derivatives to treat hepatocellular carcinoma (HCC). The biotech cited an animal...
14:13 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Skin cancer Mouse studies suggest dual inhibition of MAP2K1/MAP2K2 or MAPK1/MAPK3 could help treat PTEN hamartoma tumor syndrome (PHTS), a type of skin hyperplasia that can become malignant. In a mouse model of PHTS, dual...
07:00 , Oct 10, 2016 |  BioCentury  |  Emerging Company Profile

Pellino play

Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc.'s anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical and...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...